COVID-19 infection in a patient with multiple sclerosis treated with fingolimod

In this case report recently published in Neurology, Barzegar et al. present the case of a 42-year-old woman affected by relapsing-remitting MS treated with fingolimod who was diagnosed with COVID-19 and had a favourable outcome.

In this case report recently published in Neurology, Barzegar et al. present the case of a 42-year-old woman affected by relapsing-remitting MS treated with fingolimod who was diagnosed with COVID-19 and had a favourable outcome. Despite multiple comorbidities, the COVID-19 infection was resolved with a good outcome, and there was no need for intensive care or intubation. Interestingly, the initial presentation of COVID-19 was worsening of neurological symptoms, which is commonly seen in patients with MS in the context of infections. Indeed, the authors suggest that pseudoexacerbations or relapses without a clear aetiology should prompt COVID-19 testing in these patients during the pandemic.
https://nn.neurology.org/content/7/4/e753

by Marialuisa Zedde and Francesco Cavallieri